Abeprazan hydrochloride_product_DataBase

Bioactivity	Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1].
Invitro	The mechanism of action of Abeprazan hydrochloride is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation[1].
In Vivo	Abeprazan hydrochloride (DWP14012 hydrochloride) inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion is equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1].
Name	Abeprazan hydrochloride
CAS	1902954-87-3
Formula	C19H18ClF3N2O3S
Molar Mass	446.87
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	-20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218.

PeptideDB